4.11: Factors Affecting Protein-Drug Binding: Drug-Related Factors

Drug binding to proteins is a complex phenomenon influenced by various drug-related factors, each playing a significant role in the interaction between drugs and proteins within the body.

One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In contrast, drugs with lower lipophilicity, such as ampicillin, exhibit lower binding extents, around 20%. Additionally, highly lipophilic drugs tend to localize in adipose tissues.

The ionization state of a drug also influences its protein binding. Anionic drugs such as penicillins and sulphonamides have a higher affinity for human serum albumin (HSA), while cationic drugs such as imipramine and alprenolol tend to bind to α₁-acid glycoprotein (AAG). Unionized drugs that do not carry a charge, such as propranolol, bind more to lipoproteins.

Furthermore, the extent of protein-drug binding is not static; it changes with variations in drug and protein concentrations. In the case of HSA, drug concentration often doesn't influence binding significantly, as therapeutic concentrations are generally insufficient to saturate it. However, certain drugs, such as lidocaine, can saturate AGP due to its lower concentration in the blood, leading to a different binding behavior.

Additionally, some drugs exhibit specific affinities for particular proteins within the body. For instance, digoxin demonstrates a higher affinity for cardiac muscle proteins than those in skeletal muscles. Lidocaine has a greater affinity for AAG than for HSA. Iophenoxic acid has a very high affinity for plasma proteins. These examples highlight the intricate and selective nature of drug-protein interactions.

Understanding these diverse factors is crucial in pharmacology, as they impact drug distribution, efficacy, and potential interactions within the body. Researchers and healthcare professionals rely on this knowledge to optimize drug therapies, minimize adverse effects, and ensure the safe and effective use of medications in clinical settings.

Protein-drug binding can be affected by various drug-related factors.

The degree of protein binding is closely related to a drug's lipophilicity, with more lipophilic drugs exhibiting higher binding. For instance,  highly lipophilic cloxacillin binds to proteins at a 95% efficiency, while less lipophilic ampicillin binds at only a 20% efficiency.

Highly lipophilic drugs tend to localize in adipose tissues.

Additionally, drug ionization influences protein binding. Anionic drugs like penicillin G preferentially bind to human serum albumin or HSA, while cationic drugs like imipramine bind to α₁-acid glycoprotein or AAG. Unionized drugs exhibit stronger binding to lipoproteins.

The extent of protein-drug binding fluctuates with drug and protein concentrations.

While drug concentration has a limited effect on HSA binding as therapeutic concentrations are generally insufficient to saturate it, AAG can be saturated by lidocaine at therapeutic levels due to its lower blood concentration.